Sex: F
Vaccine: VARZOS
Symptoms: Arthralgia, Gait disturbance, Headache, Herpes zoster, Loss of personal independence in daily activities
Clinical narrative: having pain throughout her body / pain/Sitting in a comfy chair would cause pain; could barely walk; unable to get up when squatting; fatigue; shingles; headaches; joint pain; Muscle pain; This case was reported by a consumer via patient support programs and described the occurrence of general body pain in a 65-year-old female patient who received mepolizumab (Nucala) solution for injection in pre-filled pen for drug use for unknown indication.   Co-suspect products included mepolizumab autoinjector device (Nucala Autoinjector Device) administration system for drug use for unknown indication and Herpes zoster (Shingrix) for prophylaxis.   Additional patient notes included Other Conditions were unknown .   In August 2022, the patient started Nucala at an unknown dose and frequency and Nucala Autoinjector Device. In June 2022, the patient received Shingrix. In 2022, less than 5 months after starting Nucala, an unknown time after starting Nucala Autoinjector Device and less than 6 months after receiving Shingrix, the patient experienced headache, joint pain and muscle pain. On 7th January 2023, the patient experienced activities of daily living impaired and fatigue. In January 2023, the patient experienced shingles. On an unknown date, the patient experienced general body pain and walking difficulty. The patient was treated with paracetamol (Tylenol). Nucala was continued with no change. On an unknown date, the outcome of the general body pain, headache, joint pain, muscle pain, activities of daily living impaired, fatigue, shingles and walking difficulty were unknown.   It was unknown if the reporter considered the general body pain, headache, joint pain, muscle pain, activities of daily living impaired, fatigue, shingles and walking difficulty to be related to Nucala, Nucala Autoinjector Device and Shingrix. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   GSK receipt date: 09 Feb 2023 Reporter comments: Reason for no Batch / Lot number of Nucala was Unknown. Expiry Date of Nucala was Unknown. The patient mentioned she was very active before taking Nucala. Patient scared to take medication because she was nervous she would back to having pain throughout her body. Patient stated she got the Shingrix shot in June 2022, but 4 days later she got Shingles. Patient stated she did not take the 2nd dose per Provider request. Patient received first dose of Nucala in August. Patient began to experience headaches (Tylenol) and intermittent joint/muscle pain in November/December 2022. On 07 Jan 2023, stated she was unable to get up when squatting and fatigue had been immense. Patient stated Later patient was diagnosed with Shingles again in January. In January Patient stated Sitting in a comfy chair would cause pain and could barely walk. Patient complained because she was unable to speak with a Nurse regarding the side effects. The patient stated we could follow up with her if there were additional questions. Reporter consent to contact given as Yes.; Sender's Comments:  US-GSK-US2023021101:Same reporter